Background. The Determine TB-LAM (LF-LAM) can detect lipoarabinomannan, a glycolipid found in mycobacteria, in the urine of HIV-infected patients with disseminated TB. Whether disseminated nontuberculous mycobacterial (NTM) infection causes false-positive results has not been adequately assessed.
Methods. We retrospectively reviewed the LF-LAM results and the evidence for tuberculosis (TB) coinfection among HIV-infected subjects with microbiologically confirmed disseminated NTM infection seen by the infectious diseases consultation service at a tertiary hospital in Johannesburg, South Africa.
Results. 26 patients had disseminated NTM infection, and 83 mycobacterial cultures and Xpert MTB/RIF assays were performed on these patients. All patients had specimens collected from a minimum of two different sites (e.g., blood and sputum), and the median number of specimens taken per patient was three. On the basis of this, three subjects were diagnosed with TB-NTM coinfection. LF-LAM was performed on 23 out of 26 subjects with disseminated NTM disease, and was positive in 21 cases (91.3%, 95% CI 73.2-97.6). Excluding subjects in whom TB coinfection was diagnosed, LF-LAM was positive in 19/21 cases (90.5%, 95% CI 71.1-97.4).
Conclusion. Our study revealed an unexpectedly high rate of LF-LAM positivity in patients with disseminated NTM infection. While it cannot be definitively determined whether these findings represent undiagnosed concomitant disseminated TB infection, cross-reactivity with NTM antigens, or a combination of the two, it is plausible that NTM cross-reactivity may account for at least some of the positive LF-LAM results seen in this study. In vitro studies have suggested this possibility, but previous studies assessing LF-LAM's specificity have enrolled patients whose median CD4 counts were too high to have been at substantial risk for disseminated NTM infection. To the degree that these findings can be confirmed in similar high-burden TB-HIV coinfection settings, they suggest that positive LF-LAM results should be interpreted with caution in patients with very low CD4 counts.
Disclosures. October 7, 2017: 12:30 PM Background. The QuantiFERON®-Tb Gold In-Tube (QFT) assay is an in vitro diagnostic test for Mycobacterium tuberculosisinfection. We observed a high indeterminate rate among inpatients at Steven and Alexandra Cohen Children's Medical Center of New York. We hypothesized this was caused by incorrect specimen collection. We educated healthcare workers in proper collection techniques and studied the effect on the indeterminate rate.
Methods. We recorded the results of the QFT test for pediatric inpatients from November 2012 to December 2016 from a laboratory specimen log. Beginning in April 2015, multimode education was implemented using an instructional card that accompanied the QFT tubes, presentations, and an instructional video. We used an electronic survey to assess knowledge of healthcare workers before and after the education intervention. We abstracted demographic, clinical, and laboratory factors to analyze correlation with the indeterminate rate.
Results. There were 216 subjects, 101 during the pre-education period and 115 during the post-education period. Ninety-three (43.1%) were indeterminate, 8 (3.7%) were positive, and 115 (53.2%) were negative. There was no significant difference in indeterminate result rate between pre and post-education groups, 46% and 40%, respectively (P = 0.33). In a multivariable model of factors associated with an indeterminate result, there was no significant association with education (P = 0.86), immunocompromised status (P = 0.6009), or comorbidities (P = 0.15). Age (P = 0.0007), absolute lymphocyte count (ALC) (P = 0.0016), and recent receipt of immunosuppressive medication (IS) (P = 0.0001) were significantly associated with an indeterminate result. Among those surveyed after the education period there was a significantly higher proportion of persons who received training (P < 0.0001), reported shaking the tubes after blood inoculation (P < 0.0001), and reported using a waste tube before collection (P < 0.0001) compared those surveyed prior to the education period.
Conclusion. Although education resulted in an increase in knowledge of correct specimen collection, the indeterminate rate remained high. Younger patient age, recent receipt of IS, and lower ALC are factors associated with an indeterminate result.
Disclosures. All authors: No reported disclosures. Background. Tuberculosis (TB) is a significant global health problem. Nucleic acid amplification tests (NAATs) are valuable in reducing delays to initiation of therapy and infection control protocols. A retrospective study was performed to assess the utilization and performance of a laboratory developed Mycobacterium tuberculosis complex (MTBC) PCR assay (TBPCR) for diagnosis of pulmonary (PTB) and extrapulmonary (EPTB) tuberculosis.
Utilization and Performance of a Laboratory Developed Nucleic Acid Amplification Test for the Diagnosis of Pulmonary and Extrapulmonary Tuberculosis in a Low
Methods. Study site was a 4 hospital system in suburban Chicago. All culture confirmed TB specimens with complete laboratory data from January 2002 to December 2016 were included. Patient records were accessed using an electronic data warehouse, following approval from Institutional Review Board. Standard microbiology procedures were followed for smear and culture of MTBC. A lab-developed real time PCR targeting a 123 bp region of the IS6110 insertion sequence of MTBC was performed on smear positive specimens or if ordered by physician. Clinical and laboratory data was compared with TBPCR results for all culture confirmed cases.
Results. There were 151 culture positive patients and 2186 TBPCR performed. Median age of patients at diagnosis was 49 years (IQR 33-66), 74 (49%) were female and 14 were on immunosupressive therapy. The mean number of samples tested per patient was 2. Of culture positive specimens, 59% were from a respiratory source and 3 were MDR; ordering of TBPCR was higher in specimens from PTB source (58.4%) as compared with EPTB source (37%). Combined sensitivity of the TBPCR on all specimen types was 86.6% (95% CI 76.3-93.1); 90.3% for PTB specimens alone (95% CI 78.2-96.4). Specificity was 100% (95% CI 99.5-100), PPV 100% (95% CI 90.5-100%) and NPV 99.5% (95% CI 98.8-99.8%), and were similar for all specimen types. Sensitivity of TBPCR was 97% in smear positive and 79% in smear negative PTB specimens. The median time to culture positivity was 7 days longer in specimens that were TBPCR negative compared with those that were positive (P = 0.14, NS), however, TBPCR shortened time to diagnosis by 13 days.
Conclusion. We found TBPCR to be underutilized in both PTB and EPTB although it was found to be a rapid and reliable method for early diagnosis. Education regarding utility of NAATs could be useful in low burden areas where paucibacillary disease is more common, especially in EPTB.
Disclosures. All authors: No reported disclosures. Background. This study was done to investigate the utility of specific fluoroquinolone mutations in LPA in predicting the susceptibility in DST at WHO recommended Critical Concentrations of 0.5 and 2 µg/dL of moxifloxacin within a short time frame as provided by LPA.
Correlation of Specific Mutations in Line Probe
Methods. In a retrospective study performed at a tertiary care hospital of Mumbai, India from October 2015 to February 2017, consecutive samples demonstrating fluoroquinolone resistance by LPA were selected. The LPA kit used was Hain Lifescience Genotype MTBDRsl (Version 1). It detects the following mutations in gyrA gene: MUT1: Ala90Val, MUT2: Ser91Pro, MUT3A: Asp94Ala, MUT3B: Asp94Asn/ Tyr, MUT3C: Asp94Gly, MUT3D: Asp94His. The causal mutation was noted. For 89 of these samples, DST had been requested and results with Critical Concentration of 0.5µg/dL and 2µg/dL for moxifloxacin were available
Results. The 89 samples studied were as follows: Sputum (n = 60), paravertebral soft tissue (n = 2), bronchoalveolar fluid (n = 2), cerebrospinal fluid (n = 1), endotracheal tube secretion (n = 1), pleural fluid (n = 1) and site not recorded (22). 3 of these samples had double mutations. Results are as follows.
Mutation in gyrA gene
Number of samples (n) Conclusion. This study showed a higher proportion of M. tuberculosis susceptibility at 2 µg/dL rather than at 0.5 µg/dL, to moxifloxacin for gyrA mutations Ala90Val (MUT1), Asp94Ala (MUT3A), Asp94Gly (MUT3C), Asp94His (MUT3D) but not for Ser91Pro (MUT2) and Asp94Asn/Tyr (MUT3B). However, the number of samples with Ser91Pro (MUT2) and Asp94Asn/Tyr (MUT3B) mutations was too small for meaningful conclusion. This susceptibility at a higher critical concentration of moxifloxacin may have clinical implications for use of high dose moxifloxacin. Since this information is available within a short time frame as provided by LPA, a more effective regimen could be devised 4 to 8 weeks earlier than after results of DST. This may result in faster sputum conversion and prevent amplification of resistance.
Disclosures. All authors: No reported disclosures.
Lateral Flow Urine Lipoarabinomannan Assay (LF-LAM) for Diagnosis of Active Tuberculosis in HIV-Infected Adults: a Prospective Cohort Study
Munjit Na Songkhla, MD 1 ; Hutsaya Tantipong, MD 1 ; Sasima Tongsai, Phd 2 and Nasikarn Angkasekwinai, MD Methods. We prospectively recruited HIV-positive adult patients with CD4 count less than or equal to 200/mm 3 and symptoms suspected of active TB from two tertiary hospitals between December 2015 and March 2017. Freshly collected urine was applied to the Determine ® -TB LAM Ag test strip (4 bands of graded intensity), using grade 1 cutoff. Diagnostic accuracy of urine LAM strip test were assessed against microbiological reference standard, defined as positive Mycobacterium tuberculosis cultured from one or more clinical specimens (definite TB) or composite reference standard including definite TB and probable TB, defined as those have symptoms consistent with TB and response to anti-TB treatment.
Results. A total of 280 patients were enrolled. Of whom, 72 (25.7%) and 65 (23.2%) had definite and probable TB. Amongst those with definite TB, LF-LAM test gave a sensitivity of 75.0% (95% CI 63.9-83.6), specificity of 86.0% (95% CI 79.4-90.8) and accuracy of 82. . When compared with the composite reference standard, the test yielded a lower sensitivity (61.3%, 95% CI 53.0-69.1) and accuracy (73.9%, 95% CI 68.5-78.7), with equal specificity. The test showed the highest sensitivity (90.5%, 95% CI 77.9-96.2) and accuracy (85.9%, 95% CI 79.2-90.7) but lower specificity (84.0%, 95% CI 75.6-89.9) in HIV-infected patients with CD4 count less than 50/mm 3 . The sensitivity of the combined LF-LAM or sputum microscopy was higher than that of either test alone (86.1% vs. 75.0%, 61.1%, respectively) . Mycobacterium avium complex (MAC) was cultured in 7 out of 20 with false positive result. Urine LAM strip test can remain positive for up to 4 weeks even after anti-TB treatment.
Conclusion. Urine LAM assay gave the best performance for diagnosis of active TB in advanced HIV-infected patients and provide an additional benefit of a greater simplicity, speed, with a more easily obtainable sample.
Disclosures. All authors: No reported disclosures. Background. Prompt and accurate identification and differentiation of Mycobacterium tuberculosis-complex (MTBC) from non-tuberculous mycobacteria (NTM) is crucial for the selection of antimicrobial treatment and appropriate public health response. Diagnosis and characterization of mycobacteria is challenging due to diverse clinical presentations, lack of sensitivity of smear microscopy, and fastidious culture identification. Moreover, because of clinical suspicion of noninfectious conditions, specimens are often not processed for culture and formalin-fixed, paraffin-embedded (FFPE) tissues are the only specimens available. For rapid and accurate identification of Mycobacterium spp. from patient tissues, sensitive and specific molecular assays combined with other tissue-based methods are vital.
Improved Detection and Accuracy of
Methods. We extracted DNA from FFPE tissues from 931 patients with clinical and histopathological suspicion of mycobacterial infection (received during 2013-2016) and evaluated by multistage, multigene targeted Mycobacterium-genus, complexes-and species-specific PCR assays (targets including 16S rRNA, rpoB, groEL, IS6110, RLEP) and sequencing. Tissues were also examined by acid-fast bacilli (AFB) stains and mycobacteria immunohistochemistry (IHC). Assays to detect mutations associated with drug resistance were performed on MTBC cases.
Results. A Mycobacterium species was detected in 465 (50%) cases by PCR and sequencing. Of these, 380 (82%) were positive by Mycobacterium PCR targeting 16S rRNA. 85 cases (18%), including 9 MTBC, 12 M. avium complex and 3 M. leprae, were positive by other PCRs. Co-infection of MTBC and NTM spp. was detected in 5 cases. Of 465 PCR positive cases, 327 (70%) showed immunostaining and 223 (48%) were AFB-positive. Molecular markers for drug resistance were detected in 9 out of 88 (10%) tested MTBC cases.
